The bone marrow and stem cell transplant research program at Penn brings together a multidisciplinary group of basic scientists and clinical investigators whose purpose is to investigate ways of using stem cells for new cancer treatments.
Having performed over 3000 transplants over the past two decades, the bone marrow and stem cell transplant program at Penn is one of the largest in the nation. Research in this program is focused on:
- Using cellular and vaccine immunotherapy to decrease disease relapse after autologous and allogenic transplantation
- Reduced intensity allogeneic transplantation and novel pharmacologic approaches to decrease toxicity
- Improving allogeneic transplant transplant and donor availability through the use of expanded and activated umbilical cord stem cells
- Testing new methods to prevent Graft-versus-host disease (GVHD) that may make transplant safer
- Studying new approaches to autologous stem cell transplant incorporating vaccine therapies and novel medical therapies before and after transplant
Bone marrow and stem cell transplant research at Penn is accomplished through the Abramson Cancer Center's National Cancer Institute-approved and funded Hematologic Malignancies Program.
Penn investigators are founding members and leaders of the National Institutes of Health (NIH) funded Blood and Marrow Clinical Trials Network (BMT-CTN), dedicated to conducting cutting edge clinical trials of novel approaches to improve the outcome of autologous and allogeneic stem cell transplatation.
The research program benefits from a close collaboration with the Clinical Cell and Vaccine Production Facility which performs cell and biologic processing and expansion on a range of different cell types, including:
- Bone marrow and umbilical cord blood derived lymphocytes
- Dendritic cells
- Mesenchymal stem cells
- Smooth muscle
- Endothelial cells in support of cell, vaccine and gene therapy clinical trials.
Medical oncologists who perform bone marrow and stem cell transplants include: